<DOC>
	<DOC>NCT02858856</DOC>
	<brief_summary>This is a pilot study that investigate efficacy and safety of Deciten granule on immunity of patients with breast carcinoma receiving chemotherapy.</brief_summary>
	<brief_title>Clinical Trial of Deciten Granule on Immunity of Breast Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma</mesh_term>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>men and women aged over 18 years patients who have histologically or cytologically confirmed breast tumor patients who applicable AC(doxorubicin + cyclophosphamide) ECOG score 0 to 2 patient impossible to orally intake patient with dementia, delirium and depression patient suffering from diseases like chronic hepatitis B, C or hepatocirrhosis severe liver disability (3fold the normal high range value for ALT, AST) patient who has diabetes not controlled by diet, hypertension, hyperthyroidism, severe systemic disease use of other investigational products within the past 30 days hypersensitivity to investigational product others who are judged not to be appropriate to study</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2016</verification_date>
</DOC>